Watchlist Price Alert

BioMarin Pharmaceutical I... (BMRN)

NASDAQ: BMRN · Real-Time Price · USD

57.50

0.33 (0.58%)

At close: Jul 03, 2025, 3:45 PM

56.05

-2.52%

After-hours: Jul 03, 2025, 04:55 PM EDT

0.58% (1D)

Bid	54.91
Market Cap	11.03B
Revenue (ttm)	2.94B
Net Income (ttm)	523.88M
EPS (ttm)	2.7
PE Ratio (ttm)	21.3
Forward PE	13.66
Analyst	Buy

Ask	60.6
Volume	1,376,747
Avg. Volume (20D)	2,495,018.4
Open	57.46
Previous Close	57.17
Day's Range	57.03 - 58.07
52-Week Range	52.93 - 94.85
Beta	0.18

About BMRN

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol BMRN

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for BMRN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

BioMarin Pharmaceutical Inc. is scheduled to release its earnings on Aug 4, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

4 months ago

+4.76%

BioMarin Pharma shares are trading higher after th... Unlock content with Pro Subscription

4 months ago

+1.16%

BioMarin Pharma shares are trading higher after the company reported better-than-expected Q4 financial results.

News

1 week ago · zacks.com

Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

1 week ago · zacks.com

Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

1 month ago · fool.com

Here Are All 6 Stocks I've Bought Through 5 Months of 2025

It's been a wild ride for the stock market through the first five months of 2025. As of mid-February, Wall Street's major stock indexes could do no wrong, with the benchmark S&P 500 vaulting to an all...

1 month ago · finbold.com

2 top value stocks to buy for second half of 2025

The second half of 2025 is fast approaching, and the stock market is promising a crazy ride with some exciting news hitting the headlines.

1 month ago · zacks.com

Is the Options Market Predicting a Spike in BioMarin Pharmaceutical Stock?

Investors need to pay close attention to BioMarin Pharmaceutical stock based on the movements in the options market lately.

1 month ago · zacks.com

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

1 month ago · businesswire.com

INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZY

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inozy...

1 month ago · zacks.com

BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz

BMRN's acquisition of INZY is set to add a late-stage enzyme replacement therapy for a rare genetic condition. The deal is likely to be closed by September.